On November 12, Yuekang Pharmaceutical announced that its subsidiary, Yuekang Kechuang, has received FDA approval for its Investigational New Drug (IND) application (IND number 183460) for YKYY018, a nebulized inhalation therapy developed for the treatment and prevention of human parainfluenza virus infection. The drug is a first-in-class membrane fusion inhibitor independently developed by the company using a full-process AI platform. It has previously been cleared by both the FDA and China's NMPA to enter clinical trials targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), with a Phase II clinical study for RSV currently underway. This latest approval further expands the product's clinical development footprint in the prevention and treatment of respiratory viral infections. However, the outcomes of subsequent research, development, and regulatory approvals remain uncertain.